-
Durvalumab, sold
under the
brand name Imfinzi, is an anti-cancer
medication used for
treatment of
various types of cancer. It was
developed by Medimmune/AstraZeneca...
-
Evaluation and Research. "Approved
Drugs –
Durvalumab (Imfinzi)". fda.gov.
Retrieved 6 May 2017. "FDA
approves durvalumab after chemoradiation for unresectable...
-
combination with
durvalumab, for the
treatment of
adults with
unresectable hepatocellular carcinoma.
Tremelimumab in
combination with
durvalumab and platinum-based...
-
clinical trials for
gastric cancer.
Durvalumab (Imfinzi) is a
fully human IgG1
antibody developed by AstraZeneca.
Durvalumab is FDA
approved for the treatment...
- Budesonide/glycopyrronium bromide/formoterol
Candesartan Dapagliflozin Disufenton sodium Durvalumab Eculizumab Esomeprazole Exenatide FluMist Fulvestrant Gefitinib Glycopyrronium...
- FDA :
Drugs (May 31, 2022) "FDA
approves tremelimumab in
combination with
durvalumab for
unresectable hepatocellular carcinoma". Food and Drug Administration...
- Budesonide/glycopyrronium bromide/formoterol
Candesartan Dapagliflozin Disufenton sodium Durvalumab Eculizumab Esomeprazole Exenatide FluMist Fulvestrant Gefitinib Glycopyrronium...
- Budesonide/glycopyrronium bromide/formoterol
Candesartan Dapagliflozin Disufenton sodium Durvalumab Eculizumab Esomeprazole Exenatide FluMist Fulvestrant Gefitinib Glycopyrronium...
-
include pembrolizumab, nivolumab, ipilimumab, avelumab, atezolizumab, and
durvalumab. From a
total 5,898
patients who
received these drugs, 52
developed new...
- Budesonide/glycopyrronium bromide/formoterol
Candesartan Dapagliflozin Disufenton sodium Durvalumab Eculizumab Esomeprazole Exenatide FluMist Fulvestrant Gefitinib Glycopyrronium...
